Google
 
Google

World Stem Cell Summit 2010

Friday, May 16, 2008

[StemCells] Off-the-shelf bone graft

NuVasive Acquires First Stem Cell Bone Graft Substitute


New technologies will drive US bone graft substitute market to reach
almost
$1.9 billion by 2012, according to Millennium Research Group

WALTHAM, Mass., May 14 /PRNewswire/ -- With the acquisition of
Osiris
Therapeutics' Osteocel business, NuVasive has obtained the first
off-the-shelf bone graft substitute (BGS) product to incorporate
viable
stem cells. Mounting surgeon excitement about this new BGS and other
innovative products will drive the BGS market to $1.9 billion in 2012,
according to Millennium Research Group's US Markets for Orthopedic
Biomaterials 2008 report.

"The popularity of advanced BGS technologies has increased
competition
within the field. Medtronic Spinal and Biologics' INFUSE BGS, based
on a
recombinant human bone morphogenetic protein, has forced NuVasive and
other
BGS competitors to dramatically innovate," says Kevin Flewwelling,
Orthopedics Research Manager at Millennium Research Group. "In 2007,
INFUSE
sales exceeded $700 million in the US and NuVasive saw an opportunity
to
compete against this very successful product."

In order to compete against these advanced BGS, other
manufacturers of
traditional BGS products -- such as demineralized bone matrices and
synthetics -- are developing next-generation products that offer
improved
ease-of-use and superior bone healing and regrowth. Companies claim
that
these new features eliminate the need for autograft bone harvested
from the
patient's iliac crest, reducing postoperative pain and morbidity at
the
donor site. With these greater advantages, surgeons are shifting
towards
these newer devices. A survey of surgeons conducted by Millennium
Research
Group found that 30.3% expected to perform fewer procedures using only
autograft bone by 2012.

In addition to the BGS market, the US Markets for Orthopedic
Biomaterials 2008 report covers the hyaluronic acid
viscosupplementation,
machined bone interbody device, knee cartilage repair, and cell
concentration system markets. The report also provides coverage of
all key
industry competitors, including AlloSource, Biomet, Blackstone
Medical/Orthofix, DePuy, Exactech, Ferring Pharmaceuticals, Genzyme
Biosurgery, Integra LifeSciences/IsoTis, LifeNet Health, Medtronic
Spinal
and Biologics, Musculoskeletal Transplant Foundation, Orthovita,
Osiris
Therapeutics, Osteotech, RTI Biologics, sanofi-aventis, Smith &
Nephew,
Stryker, Synthes, and Wright Medical Technology. Other reports in this
series cover Europe (France, Germany, Italy, Spain, and the UK) and
Japan.

About Bone Graft Substitutes

BGS are classified under the broader term of bone grafts. Bone
grafts
are used to promote bone healing and regrowth and fill bone voids in
spinal
fusion, trauma surgery, joint revision and reconstruction, and
craniomaxillofacial surgery. These products can be classified into six
categories: autograft, nonproprietary allograft, demineralized bone
matrix,
synthetics, growth factors -- such as bone morphogenetic proteins --
and
stem cell products. Autograft is the only bone graft material that is
taken
from a patient's own body. Other bone graft materials are commonly
referred
to as BGS.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision
Resources, Inc.
company (http://www.DecisionResources.com), is the global authority
on medical
technology market intelligence and a leading provider of strategic
information to the health care sector. Focused solely on the medical
device, pharmaceutical, and biotechnology industries, the company
provides
its clients with the benefits of its specialized industry expertise
through
published reports and customized consulting services.

All company, brand, or product names contained in this document
may be
trademarks or registered trademarks of their respective holders.

For more information, contact:
Amy Krohn
Millennium Research Group
416-364-7776 x101
akrohn@mrg.net

http://www.prnewswire.com/cgi-bin/stories.pl?
ACCT=104&STORY=/www/story/05-14-2008/0004813295&EDATE=


__._,_.___
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Recent Activity
Visit Your Group
Yahoo! News

Get it all here

Breaking news to

entertainment news

Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

Find Balance

on Yahoo! Groups

manage nutrition,

activity & well-being.

.

__,_._,___
Google

Any Comments ?.......

E-mail: manojhind2001us@gmail.com
Google
 

World Time